男性停用雄激素滥用后第一年的临床特征:社区居住研究
过去使用者报告的情绪、焦虑、性功能和生活质量均显著差于非使用者,多变量分析显示精神疾病共病与抑郁、焦虑及较差生活质量独立相关,而较低睾酮仅与抑郁症状呈 modest 关联。结论提示心理症状和生活质量下降更多与精神疾病共病相关,而非生化恢复。
要点
- 停用雄激素第一年内,过去使用者情绪、焦虑、性功能及生活质量显著差于非使用者。
- 精神疾病共病独立关联抑郁、焦虑和较差生活质量,而非生化恢复指标。
- 较低睾酮仅与抑郁症状呈 modest 关联,支持心理行为干预而非药物。
核心结论
- 停用雄激素滥用后第一年,心理症状和生活质量下降与精神疾病共病关联最强,而非生化恢复。
研究设计与样本
- 参与者完成雄激素和物质使用问卷及4种验证量表,并进行晨间空腹血清激素分析和筛查以排除未披露的雄激素使用。
主要发现
- 当前使用者和过去使用者自报精神疾病诊断是非使用者的2.5倍。
- 当前使用者总睾酮最高(P < .001),过去使用者与非使用者无差异。
- 过去使用者报告的情绪、焦虑、性功能和生活质量显著差于非使用者。
- 多变量分析显示精神疾病共病独立关联抑郁(P = .001)、焦虑(P < .001)和较差生活质量(P < .05)。
- 年龄较大和较高促黄体生成素与性功能降低相关(P < .05),较低睾酮仅与抑郁症状呈 modest 关联(P = .03)。
临床怎么用
- 对停用雄激素滥用男性,应评估精神疾病共病,而非仅关注睾酮水平。
- 支持开发心理和行为干预而非药物干预来帮助雄激素停用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Androgen abuse is an increasing public health concern, particularly among young men seeking muscular or image enhancement. Although most achieve biochemical recovery within 12 months of cessation, mood disturbances, sexual dysfunction, and fatigue are widely reported for years afterward. OBJECTIVE: To examine symptom severity the relationship to biochemical recovery during the first year after androgen abuse cessation. METHODS: We conducted a cross-sectional study of community-dwelling men grouped as nonusers, current users, or past users who had ceased within the last 12 months. Participants completed questionnaires on androgen and substance use and 4 validated instruments assessing mood (Beck Depression Inventory-II), anxiety (Generalized Anxiety Disorder-7), sexual function (International Index of Erectile Function-15), and quality-of-life (36-item Short Form). Morning fasted serum hormonal analysis and screening to exclude undisclosed androgen use were performed. RESULTS: Two hundred forty-seven men were included: 50 nonusers, 125 current users, and 72 past users. Self-reported psychiatric diagnoses were 2.5-fold higher among current and past users than nonusers. Total testosterone (TT) was highest in current users (P < .001) with no difference between past and nonusers. Past users reported significantly worse mood, anxiety, sexual function, and quality of life vs nonusers. Multivariable analyses showed psychiatric comorbidity was independently associated with depression (P = .001), anxiety (P < .001), and poorer quality-of-life (P < .05). Older age and higher luteinizing hormone were associated with reduced sexual function (P < .05), while lower testosterone showed only a modest association with depressive symptoms (P = .03). CONCLUSION: Among men in the first year after stopping androgen abuse, psychological symptoms and reduced quality-of-life were most strongly associated with psychiatric comorbidity than biochemical recovery. These findings challenge the assumption that androgen withdrawal symptoms are predominantly driven by hypogonadism and supports developing psychological and behavioral interventions, rather than pharmacological, to support androgen withdrawal in men.
引用
- Grant B, Kean J, de Silva NL, et al. Clinical features of androgen abuse withdrawal in men during the first year of cessation: a community dwelling study. J Clin Endocrinol Metab. 2026. PMID: 41818709. doi:10.1210/clinem/dgag110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。